Objective: To investigate the clinical effect of Aidi injection combined with TACE on patients with primary liver cancer and its influence on serum AFP, bFGF, VEGF, inflammatory cytokines, immune function and quality of life. Methods From June 2017 to June 2019, 116 patients with primary liver cancer from Shanghai Yangsi hospital and Zhongshan Hospital Affiliated to Fudan University were selected as the study objects. They were randomly divided into TACE group and TACE + Aidi group with 58 cases in each group. The TACE group was treated with TACE. The clinical efficacy, serum tumor markers, bFGF, VEGF, TGF-beta 1, oxidative stress, inflammatory cytokines, cellular immune function and quality of life were observed. Results The total effective rate was 89.66％ in the case group, which was significantly higher than 74.14％ in the TACE group, The difference was statistically significant (P<0.05). After treatment, the levels of alpha-fetoprotein (AFP), carbohydrate chain antigen (CA) 242, CA724, basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), transforming growth factor-beta 1 (TGF-beta), malondialdehyde (MDA), interleukin (IL) -6, IL-10, tumor necrosis factor (TNF) -a, circulating immune complex (CIC), CD8+ in the two groups were lower than those before treatment; total antioxidant capacity (TAOC), measurement The levels of superoxide dismutase (SOD), IL-12, CD3+, CD4+, CD4+/CD8+ and QOL scores of quality of life were higher than those before treatment. The serum tumor markers, bFGF, VEGF, TGF-beta 1, oxidative stress, inflammatory cytokines, cellular immune function and quality of life in theTACE + Aidi group were significantly better than those in the TACE group. The difference was statistically significant (P<0.05). The incidence of adverse reactions in theTACE + Aidi group was 6.89％, which was lower than 13.78％ in the TACE group, There was no significant difference (P>0.05). Conclusions Addie injection combined with transcatheter arterial chemoembolization is effective in treating primary liver cancer, reducing serum tumor markers, reducing toxic and side effects, regulating oxidative stress, reducing inflammatory reaction, reducing serum bFGF, VEGF and TGF- beta 1 levels, improving the quality of life of patients, and has high efficiency and safety, which is worthy of further promotion in clinic.